Rule 497(d)
FT 422
Biotechnology Select Portfolio, Series 3
Digital Convergence Select Portfolio, Series 2
Fiber Optics Select Portfolio, Series 2
Genomics & Proteomics Select Portfolio, Series 2
Pharmaceutical Select Portfolio, Series 3
Storage & Networking Select Portfolio Series
Technology Select Portfolio, Series 3
Biotechnology Portfolio, Series 3
Digital Convergence Portfolio, Series 2
Fiber Optics Portfolio, Series 2
Genomics & Proteomics Portfolio, Series 2
Pharmaceutical Portfolio, Series 9
Storage & Networking Portfolio Series
Technology Portfolio, Series 12
Supplement to the Prospectus dated March 22, 2000
Notwithstanding anything to the contrary in the Prospectus, Unit holders who
acquire Units of Fiber Optics Select Portfolio, Series 2, Genomics & Proteomics
Select Portfolio, Series 2, Storage & Networking Select Portfolio Series,
Biotechnology Portfolio, Series 3, Digital Convergence Portfolio, Series 2,
Fiber Optics Portfolio, Series 2, Genomics & Proteomics Portfolio, Series 2,
Storage & Networking Portfolio Series or Technology Portfolio, Series 12 which,
as a result of a reduction in the aggregate underlying value of
the Securities, are not subject to an initial sales charge will be subject to
the maximum remaining deferred sales charge (initially $.225 per Unit in the
case of Fiber Optics Select Portfolio, Series 2, Genomics & Proteomics Select
Portfolio, Series 2 and Storage & Networking Select Portfolio Series or $.35
per Unit for Biotechnology Portfolio, Series 3, Digital Convergence Portfolio,
Series 2, Fiber Optics Portfolio, Series 2, Genomics & Proteomics Portfolio,
Series 2, Storage & Networking Portfolio Series or Technology Portfolio,
Series 12). In such case the maximum sales charge may exceed 3.25% of
the Public Offering Price per Unit for Fiber Optics Select Portfolio, Series 2,
Genomics & Proteomics Select Portfolio, Series 2 and Storage & Networking
Select Portfolio Series or 4.5% of the Public Offering Price per Unit for
Biotechnology Portfolio, Series 3,
Digital Convergence Portfolio, Series 2, Fiber Optics Portfolio, Series 2,
Genomics & Proteomics Portfolio, Series 2, Storage & Networking Portfolio
Series or Technology Portfolio, Series 12, but in no event will the maximum
sales charge exceed 3.75% of the Public Offering Price per Unit for Fiber
Optics Select Portfolio, Series 2, Genomics & Proteomics Select Portfolio
or Storage & Networking Select Portfolio Series,or 5.0% of the Public Offering
Price per Unit for the Biotechnology Portfolio, Series 3, or 5.5% of the Public
Offering Price per Unit for Digital Convergence Portfolio, Series 2, Fiber
Optics Portfolio, Series 2, Genomics & Proteomics Portfolio, Series 2,
Storage & Networking Portfolio Series or Technology Portfolio, Series 12.
April 14, 2000
